New CAR-T treatment targets two cancer markers in one shot
NCT ID NCT06879262
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-stage study tests a new type of CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia or non-Hodgkin lymphoma that has not responded to standard treatments. Participants receive a single infusion of immune cells designed to attack two cancer targets (CD19 and CD22). The goal is to see if the treatment is safe and can shrink or control the cancer. Follow-up lasts three years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R NHL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.